drugset / Trial / NCT03313336

A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.

NCT03313336

Phase 1 Completed 32 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverDouble-blindSupportive care

Summary

A double-blind, randomized, 2-period, placebo-controlled, single-center, crossover study, efficacy study demonstrating the therapeutic equivalence of the test cellulose disc (matrix) in EMLA patch and the current commercial cellulose disc (matrix) in EMLA patch in healthy subjects.

Timeline

Start
2017-10-30
Primary completion
2017-11-09
Completion
2017-11-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified
Comparator prilocaine Small molecule

Indications

No indication recorded.